Arginase (ARG) is an enzyme involved in urea cycle, where it catalyzes the hydrolysis of L-arginine into L-ornithine and urea. There are two distinct isoforms of arginase, arginase I and II, which are encoded by separate genes and display differences in tissue distribution, subcellular localization, and molecular regulation. Arginase activity has two major homeostatic purposes: first, to rid the body of ammonia through urea synthesis, and second, to produce ornithine, the precursor for polyamines and prolines. Polyamines produced through ornithine decarboxylase (ODC) are necessary for cell proliferation and regulation of several ion channels. Proline produced through ornithine aminotransferase (OAT) is necessary for production of collagen.

Arginase I is a cytosolic enzyme that is abundantly expressed in the liver and plays an essential role in hepatic urea cycle. In contrast, arginase II is a mitochondrial enzyme that is widely expressed outside the liver, most prominently in the kidney and prostate. Arginase functions important for protection against NH3 toxicity and cell growth and repair. Excessive arginase activity in mammals has been associated with cardiovascular and nervous system dysfunction and disease. Two relevant aspects of this elevated activity may be involved in these disease states. First, excessive arginase activity reduces the supply of L-arginine needed by nitric oxide (NO) synthase to produce NO. Second, excessive production of ornithine leads to vascular structural problems and neural toxicity. In addition, Arginase is a potential therapeutic target for the treatment of sexual arousal disorders in men and women.
Arginase Inhibitors

2-Aminoimidazole
Cat. No.: HY-W062216
2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits.
Purity: 97.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg

ARG1-IN-1
Cat. No.: HY-145331
ARG1-IN-1 is a human arginase 1 inhibitor with an IC_{50} of 29 nM.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BEC hydrochloride
Cat. No.: HY-19548A
BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with K_{i} of 0.31 μM and 30 nM at pH 7.5 and pH 9.5, respectively.
Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

DL-Norvaline
Cat. No.: HY-W010510
DL-Norvaline, a derivative of L-norvaline, L-norvaline is a non-competitive inhibitor of arginase.
Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

ARG1-IN-1
Cat. No.: HY-W062216

Arginase inhibitor 1
Cat. No.: HY-15775
Arginase inhibitor 1 is a potent inhibitor of human arginases I and II with IC_{50} values of 223 and 509 nM, respectively.
Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NED-3238
Cat. No.: HY-126332
NED-3238 is a highly potent arginase I and II inhibitor with IC_{50} values of 1.3 nM and 8.1 nM, respectively.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nor-NOHA acetate
Cat. No.: HY-112885A
Nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible arginase inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism.
Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Numidargistat
Cat. No.: HY-101979
Numidargistat (CB-1158; INCB01158) is a potent and orally active inhibitor of arginase, with IC_{50} of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Numidargistat dihydrochloride
Cat. No.: HY-101979A
Numidargistat (CB-1158) dihydrochloride is a potent and orally active inhibitor of arginase, with IC_{50} of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Piceatannol 3'-O-glucoside
(Quzhaqigan) Cat. No.: HY-N2237

Piceatannol 3'-O-glucoside, an active component of Rhubarb, activates endothelial nitric oxide (NO) synthase through inhibition of arginase activity with IC$_{50}$ s of 11.22 µM and 11.06 µM against arginase I and arginase II, respectively.

**Purity:** 99.74%
**Clinical Data:** No Development Reported
**Size:** 1 mg

www.MedChemExpress.com